Gain valuable insights from The Tisch Cancer Institute at Mount Sinai—a National Cancer Institute-designated cancer center and an integral part of the Mount Sinai Tisch Cancer Center—and cancer specialists throughout the Mount Sinai Health System. Our extensive network spans cancer prevention, innovative developments in precision-medicine and immunotherapy approaches, novel treatments via clinical trials, equity in cancer care, and groundbreaking translational research.
Under the leadership of Ramon Parsons, MD, PhD, Joseph A. Sparano, MD, and Luis Isola, MD, our comprehensive cancer program is renowned for its powerful synergy between research scientists and clinicians and its multidisciplinary scope. The Mount Sinai Hospital's Department of Oncology is ranked No. 12 in the nation by U.S. News & World Report® for 2023-24.
Gain valuable insights from The Tisch Cancer Institute at Mount Sinai—a National Cancer Institute-designated cancer center and an integral part of the Mount Sinai Tisch Cancer Center—and cancer specialists throughout the Mount Sinai Health System. Our extensive network spans cancer prevention, innovative developments in precision-medicine and immunotherapy approaches, novel treatments via clinical trials, equity in cancer care, and groundbreaking translational research.
Under the leadership of Ramon Parsons, MD, PhD, Joseph A. Sparano, MD, and Luis Isola, MD, our comprehensive cancer program is renowned for its powerful synergy between research scientists and clinicians and its multidisciplinary scope. The Mount Sinai Hospital's Department of Oncology is ranked No. 12 in the nation by U.S. News & World Report® for 2023-24.
Mount Sinai's new Children’s Brain and Spinal Tumor Center will focus on innovative translational research, bridging basic science with the clinical care of children with brain and spinal tumors.
The Mount Sinai Health System’s esophagectomy program has received a three-star (excellent performance) overall composite score from the Society of Thoracic Surgeons (STS).
In the United States, cholangiocarcinoma, or bile duct cancer, is relatively rare, although its incidence is growing for reasons experts have yet to identify. Because of its rarity, research into it has been scarce. But a Mount Sinai researcher ...
A clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy with immunotherapy resulted in improved survival in patients with an advanced type of bladder cancer.
The Mount Sinai Health System has received a $12,180,625 grant from the National Heart, Lung and Blood Institute to compare new treatment options for sickle cell disease and determine which work best for specific patients.
Miriam Merad, MD, PhD, an esteemed immunologist at the Icahn School of Medicine at Mount Sinai, has been elected to the National Academy of Medicine (NAM) in recognition of her pioneering contributions to the fields of immunology and cell biology.
In a phase 2 clinical trial that was the first of its kind, doctors found that some patients could be treated with a combination of chemotherapy and immunotherapy without the need to remove their bladder.
A first-of-its-kind study unveils how diabetes drives multiple myeloma growth and differences in survival outcomes for Black versus white patients with both conditions
Graft-versus-host disease is a complication of stem cell or bone marrow transplantation with few treatment options. But Mount Sinai researchers have been working on the problem for decades, bringing innovations to the field.
The Mount Sinai Acute GVHD International Consortium comprising 25 BMT centers uses pioneering proteomic techniques to identify and validate biomarkers for skin, gut, and steroid-resistant GVHD.
Tremendous progress has been made in improved survival and quality of life for multiple myeloma patients. Continued advancements in effective treatment options has changed the outlook for patients and physicians.
Cardinale B. Smith, MD, PhD, has been appointed Chief Medical Officer for the Tisch Cancer Hospital and Vice President of Cancer Clinical Affairs, and Ash Tewari, MBBS, MCh, has been appointed Surgeon-in-Chief of the Tisch Cancer Hospital.
Immunotherapy after surgery increased bladder cancer patients’ chance of staying cancer-free compared to patients who received a placebo, according to clinical trial results shared in a late-breaking oral presentation at the American Society ...
Nina Bhardwaj, MD, PhD, was honored with the 2022 ESMO Award for Immuno-Oncology from the European Society for Medical Oncology in recognition of her outstanding contributions to cancer immunology research.
The Tisch Cancer Institute continues to benefit from the addition of topflight investigators to its diverse research team from medical centers and laboratories around the world.
Jian Jin, PhD, continues to push frontiers in oncology research at The Tisch Cancer Institute (TCI), with his latest discoveries including advances in protein degradation in breast cancer and leukemia.
The World Trade Center (WTC) Health Program at Mount Sinai has characterized differences in prostate cancer risk between that of responders to the attack and that of the general public.
Recent work with induced pluripotent stem cells has helped uncover complex mechanisms in myelodysplastic syndrome and acute myeloid leukemia for the first time. This discovery could pave the way for improving current treatments, or even for finding new ones.
The effects of ARID2 gene mutations are being explored for the first time in advanced melanoma, which not only sheds light on how those tumor cells become more aggressive, but also opens doors to better treatment and prevention strategies in the future.
A recent study in pancreatic cancer provided evidence for immunoediting in human cancers, opening up the potential for cancer vaccines that could improve survival and outcomes.
At The Tisch Cancer Institute, we are investigating the complexities of cancer biology and behavior with the goal of improving the lives of those affected by cancer and minimizing its power.
Andrea Wolf, MD, Director of the New York Mesothelioma Program at the Mount Sinai Health System, has received the prestigious 2022 Irving J. Selikoff Lifetime Achievement Award from the Asbestos Disease Awareness Organization.
The therapy, known as a bispecific antibody, binds to both T cells and multiple myeloma cells and directs the T cells—white blood cells that can be enlisted to fight off diseases—to kill multiple myeloma cells.
Raja M. Flores, MD, and Brian Housman, MD, have pioneered major modifications to the Ivor Lewis esophagectomy that make it less invasive and enable patients to recover more quickly.
Researchers at Mount Sinai’s Tisch Cancer Institute have identified a new gene that is essential to colon cancer growth and found that inflammation in the external environment around the tumor can contribute to the growth of tumor cells.
For the first time, scientists have identified a type of cancer cell in triple negative breast tumors, which is highly efficient in invading and colonizing distant organs but slow their growth upon colonization.
Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 grant from Stand Up To Cancer® (SU2C) to explore therapeutic approaches to lung tumors with mutations in the KRAS gene, an undertaking ...
The Cardio-Oncology Program at The Mount Sinai Hospital, under the directorship of Gagan Sahni, MD, has been awarded Gold Center of Excellence status. This is the highest designation of certification from the International Cardio-Oncology ...
Mount Sinai researchers have validated for the first time that a simple blood test called a liquid biopsy could be a better predictor of whether cancer immunotherapy will be successful for a patient with lung cancer than an invasive tumor biopsy procedure.
Immunotherapy after surgery helped reduce cancer recurrence in patients with urothelial cancer of the bladder or other sites in the urinary tract that had invaded the muscle...
Mount Sinai researchers have discovered a previously unknown mechanism in which not-yet-malignant cells from early breast cancer tumors travel to other organs and, eventually, “turn on” and become metastatic breast cancer.
The Canopy Cancer Collective, a national nonprofit organization that strives to fuel better treatments and outcomes for pancreatic cancer patients, has awarded The Tisch Cancer Institute at Mount Sinai a $500,000 grant to support continued ...
World Trade Center (WTC) first responders who underwent low-dose CT (computed tomography) lung screenings were three times more likely to have moderate-to-severe steatosis than others, a result much higher than expected.
Small-molecule inhibitors of the closely related cyclin-dependent kinases 4 and 6 (CDK4/6 is) that have shown success in treating patients with metastatic breast cancer have been only modestly effective against other tumor types.
Scientists led by Miriam Merad, MD, PhD, have shown for the first time that specific populations of macrophages promote tumor growth and contribute to immune evasion in early lung cancer lesions.
The search for effective new treatments for liver cancer has led Mount Sinai investigators to highly targeted compound libraries that include kinase inhibitors, histone modifying enzymes, and other small molecules used in combination with ...
A research team at The Tisch Cancer Institute, which focuses on the burgeoning field of cancer dormancy, has identified a promising strategy for preventing metastasis from occurring.
One major limitation of T-cell-based immunotherapies is a phenomenon known as “antigen escape,” which occurs when a subset of cancer cells lose the targeted antigen.
Investigators at The Tisch Cancer Institute are developing different types of personalized vaccines, including those that treat cancers with common cell mutations and those combined with checkpoint inhibitors.
Mount Sinai researchers led by Samir Parekh, MD, have found a family of three compounds that fit into a pocket on the SOX11 surface that interfere with DNA binding and block the mechanism by which mantle cell lymphoma develops.
Oren J. Becher, MD, was recently named Chief of the Jack Martin Division of Pediatric Hematology-Oncology, the Steven Ravitch Chair in Pediatric Hematology, and Professor of Pediatrics at the Icahn School of Medicine at Mount Sinai.
Investigators Ramon Parsons, MD, PhD, and Jian Jin, PhD, have engineered a synthetic compound—a small molecule called MS21— that targets the PTEN/AKT pathway, one of the most commonly mutated pathways in human cancers.
The U.S. Food and Drug Administration's recent approval of the adjuvant use of nivolumab for muscle-invasive urothelial carcinoma may set a new standard of care.
In June 2021, clinician and researcher, Joseph A. Sparano, MD, joined The Tisch Cancer Institute as Deputy Director, where he will continue to lead clinical trials and improve treatments for breast cancer and cancers associated with HIV ...
